Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
133
resultados
Última actualización
25/04/2026 [07:21:00]
Resumen de: WO2026083250A1
The objective invention provides a parenteral composition of semaglutide or a pharmaceutically acceptable salt thereof for subcutaneous administration, having a strength and composition such that it can be administered multiple times from single article of manufacture, for use in treating type 2 diabetes mellitus and for weight loss, thereby providing benefit to the patient.
Resumen de: WO2026084731A1
A multi-analyte sensor system is disclosed. The system includes a sensor probe that has a first set of electrodes that transduce glucose into electrical signals, a second set of electrodes that transduce lactate into electrical signals and a third set of electrodes that provide working and counter electrode functionality for the first and second set of electrodes. The system has an electronics module that electrically interfaces with the sensor probe, and includes a transceiver configured to transmit sensor data. The system also includes control circuitry communicatively coupled to the electronics module that determines a glucose state based on signals from the first set of electrodes and also determine a lactate state based on signals from the second set of electrodes. The control circuitry also generates an insulin infusion pump control signal based on signals from the first and second set of electrodes.
Resumen de: WO2026085278A1
Systems and methods are disclosed for managing a person's blood glucose concentration within a predetermined range by co-administration of insulin and pramlintide using an automated insulin delivery system. A model predictive control (MPC) algorithm that includes a glucoregulatory control model augmented with a compartment model of pramlintide pharmacokinetics and pharmacodynamics is utilized. In some embodiments, the person may announce in advance meals to be consumed and the pramlintide-aware MPC algorithm uses this data as input to the glucoregulatory control model. In other embodiments, an automatic meal detection and size estimation algorithm is incorporated into the system to relieve the person of the burden of meal entry and carbohydrate estimation.
Resumen de: WO2026085127A1
A method of administering insulin to a patient to achieve and maintain euglycemia is disclosed. The method includes administering insulin to the patient at a drip rate that is based on a current blood glucose level of the patient and a weight of the patient. Insulin is administered during an initial phase, a transition phase (during which blood glucose level decreases slower than during the initial phase), and a maintenance phase. During the maintenance phase, the method includes adjusting the drip rate periodically based on a current drip rate and a percentage change in blood glucose level during a period of time. In addition, the maintenance phase considers a lookback period in which the drip rate is adjusted based on trends during the lookback period.
Resumen de: WO2026085358A1
A method of improving glycemic control is provided. The method includes stimulating a cutaneous distribution of a subject's vagus nerve within the subject's ear with a nerve stimulating signal. The method also includes monitoring the subject's blood glucose. The method further includes administering insulin infusions to the subject.
Resumen de: US20260108215A1
0000 The present invention relates to a method for predicting the prognosis of intravitreal injection treatment, comprising the steps of: receiving OCT images and clinical information of a plurality of diabetic macular edema patients; extracting one or more major lesion information from the OCT images; training a multi-modal deep learning model by inputting the OCT images, the clinical information, and the one or more major lesion features, and outputting the intravitreal injection treatment prognosis of the diabetic macular edema patients; and predicting the prognosis of intravitreal injection treatment by inputting the OCT images, the clinical information, and the major lesion features of a specific diabetic macular edema patient to the trained multi-modal deep learning model.
Resumen de: AU2026202583A1
22573194_1 (GHMatters) P45417AU02 An insulin device configured to control an insulin dosage by adapting a basal rate profile. The insulin device includes a sensor configured to produce a blood glucose level measurement data, and detect changes of the blood glucose level measurement data over time; a processor and associated computer memory device configured to receive the blood glucose level measurement data and a basal rate profile, such that the basal rate profile includes a basal rate set point that corresponds to an insulin delivery reference for a nominal blood glucose, and the basal rate profile is stored in the computer memory device. The insulin device also includes an an insulin dispensing valve controlled by the processor to administer insulin in accordance with the received basal rate profile, such that the processor is configured to update the basal rate set point over a time period based on both an assessment of at least one of a risk of hyperglycemia and a risk of hypoglycemia from historical blood glucose data, and patterns of actions taken by the insulin device to mitigate glycemic risk during the time period. The insulin dispensing valve is controlled by the processor to administer insulin in accordance with the updated basal rate set point. pr p r
Resumen de: US20260108742A1
Devices and methods described herein may, among other uses, favorably cause the activation and/or deactivation of vascular baroreceptors in order to achieve a desired impact on a physiological condition, such as baroreflex-regulated conditions, hypertension, hypotension, nervous system disorders, metabolic disorders, cardiovascular disease, heart failure, cardiac arrhythmia, renal disease, respiratory disease, diabetes, and insulin resistance. The devices and methods may be used in concert with each other and/or other treatments, medications, interventions, or behavioral regimens. They may also be used in concert with devices and methods that perform or assist with assessing or measuring a mammal's blood pressure, assessing, measuring, or predicting the impact of the described methods and devices on the patient's condition (including blood pressure), and/or protecting the surrounding anatomy from adverse effects.
Resumen de: US20260112492A1
Provided are methods and systems for generating a model for determining blood glucose levels using voice samples. This includes receiving, at a processor: a plurality of voice samples from at least one subject at a plurality of time points; and a plurality of blood glucose levels, wherein each blood glucose level in the plurality of blood glucose levels is temporally associated with a voice sample in the plurality of voice samples; sorting, at the processor, the plurality of voice samples into two or more blood glucose level categories based on the blood glucose levels; extracting, at the processor, voice feature values for a set of voice features from each of the plurality of voice samples; selecting, at the processor, a subset of voice features from the set of voice features; and generating at the processor, the blood glucose level prediction model based on the subset of voice features.
Resumen de: EP4729087A1
The present application relates to the technical field of medical appliances and discloses a patch type insulin pump and an insulin injection system and its method of application. The patch type insulin pump comprises an injection module, a power module and an injection detection module. The injection module comprises a drug storage tank, a push rod piston and two conductive push rods. The bottom of the drug storage tank is provided with an injection port, and the top is provided with an opening. The push rod piston is sealed on the opening, and the push rod piston may move relative to the drug storage tank along a first direction. The two conductive push rods are respectively connected to the push rod piston. The injection detection module comprises a control circuit board, two conductive contact springs and a conductive module. The two conductive contact springs are electrically connected to the control circuit board, and the two conductive push rods are in a sliding contact with the two conductive contact springs. The power module is used to drive the conductive module to move in the first direction, and the control circuit board is used to detect the dosage injected into the drug storage tank based on the moving distance of the conductive module. The patch type insulin pump can detect the dosage injected by the patch type insulin pump.
Resumen de: EP4729088A1
The present application relates to the technical field of medical instruments, and disclosed thereby are a power device and a patch type insulin pump. The power device comprises a power output module, a transmission component, a lead screw and a sliding block, wherein the power output module comprises a power output shaft, and the power output shaft is in transmission connection to the transmission component. The transmission component is in transmission connection to the lead screw, and the transmission component is used to transfer power output from the power output shaft to the lead screw to drive the lead screw to rotate around its own axis. The sliding block is sleeved on the lead screw, and the sliding block is abutted to one end of a push rod away from a bolus piston. When the lead screw rotates around its own axis, the sliding block is driven to move relative to the lead screw along the axis direction of the lead screw, so that the sliding block drives the push rod to move along the axis direction of the lead screw. The axis of the power output shaft is parallel to the axis of the lead screw, and the power output direction of the power output shaft is opposite to the movement direction of the sliding block. The power device disclosed by the application is beneficial for reducing the volume of the patch type insulin pump.
Resumen de: US20260102473A1
There is provided inter alia an aqueous liquid pharmaceutical formulation comprising (i) an insulin compound, (ii) ionic zinc, (iii) a zinc binding species at a concentration of 1 mM or more selected from species having a log K with respect to zinc ion binding in the range 4.5-12.3 at 25° C., and (iv) a non-ionic surfactant which is an alkyl glycoside; and wherein the formulation is substantially free of EDTA and any other zinc binding species having a log K with respect to zinc ion binding of more than 12.3 at 25° C.
Resumen de: WO2026079858A1
Provided are a method for predicting an emergency room visit of a diabetic patient and a system thereof. A method for predicting an emergency room visit according to some embodiments may comprise the steps of: obtaining one or more machine-learning models prepared to predict information related to an emergency room visit of a diabetic patient; obtaining state information of a target diabetic patient; and predicting emergency room visit information of the target diabetic patient from the state information through the one or more machine-learning models. According to the method, the likelihood of a diabetic patient visiting an emergency room can be accurately predicted at an early stage.
Resumen de: WO2026080545A1
Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a "morsel track" for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.
Resumen de: US20260102124A1
Certain aspects of the present disclosure relate to methods and systems for providing decision support around glucose management for patients with diabetes. Time-varying inputs including blood glucose, meal intake information, and amount of infused insulin are processed using a machine learning model to obtain predicted glucose levels for a plurality of prediction horizons and uncertainties for the predictions. A confidence interval is generated for each prediction and the confidence intervals are compared to hypo- and hyperglycemic thresholds. If a confidence interval is entirely below or entirely above the hypo- and hyperglycemic thresholds, respectively, then a decision support output is provided.
Resumen de: US20260104765A1
Systems, devices and methods for the management of glucose levels in the body of patient featuring user interface input mechanisms configured to provide haptic feedback to the user are provided.
Resumen de: US20260106031A1
Provided is a computer-implemented device for generating a type-Il (T2DM) diabetic status prediction, including: a memory comprising a diabetic status prediction model; and a processor in communication with the memory, the processor configured to: receive a voice sample from the subject; extract at least one voice biomarker feature value from the voice sample for at least one predetermined voice biomarker feature; determine the type-II (T2DM) diabetic status prediction for the subject based on the at least one voice biomarker feature value and the diabetic status prediction model; and output, to an output device, the type-II (T2DM) diabetic status prediction for the subject or an output based on the diabetic status prediction.
Resumen de: US20260102082A1
User interfaces for glucose insight presentation are leveraged. A glucose monitoring application is configured to process glucose measurements to determine one or more glucose insights, e.g., about a user's glucose. The glucose measurements, for example, may be obtained from a glucose monitoring device that collects glucose measurements of the user at predetermined intervals, e.g., every five minutes. The glucose monitoring application configures a user interface, based on configuration data, to present one or more visual elements representative of the one or more glucose insights. For example, the glucose monitoring application may configure the user interface to include a visual element in the form of a color field which represents whether the user's current glucose measurement (e.g., the most recent glucose measurement obtained from the glucose monitoring device) is below, within, or above a glucose range.
Resumen de: WO2026079566A1
The present disclosure describes an apparatus for analyzing glucose level of a person. The apparatus configured to determine glucose levels of the person based on the measured electrical parameters and the continuously measured physiological parameters, identify a plurality of fluctuation patterns associated with the determined glucose levels of the person over the predefined time period, and analyze the plurality of fluctuation patterns to determine glucose level variability of the person. The fluctuation pattern corresponds to variations in glucose levels between successive measurement of the electrical parameters.
Resumen de: US20260102471A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
Resumen de: WO2026080527A1
Methods, systems and devices adapted to predict a glucose state of a subject. Methods may include sensing one or more biosignals with one or more wearable sensing devices; determining at least one of a heart rate (HR), heart rate variability (HRV) or information indicative thereof based on one or more sensed biosignals; predicting a glucose state of the subject based on the at least one of the heart rate, heart rate variability, or information indicative thereof; and causing the predicted glucose state to be displayed on a display of a personal device. Methods, systems and devices adapted to predict at least one of heart rate (HR), heart rate variability (HRV), or information indicative thereof, of a subject based on sensed electrical biosignals.
Resumen de: WO2026080769A1
Systems and methods are provided for a dual needle apparatus configured to couple to a reservoir of a syringe assembly with a luer lock fitting. The dual needle apparatus may include at least a first needle and a second needle, the first needle longer than the second needle. The first needle may be configured to deliver insulin from the reservoir to the interior of a medication bladder when inserted into the medication bladder. The second needle may be configured to release air or insulin from the medication bladder to an external environment responsive the pressure caused by insulin delivery through the first needle.
Resumen de: US20260102563A1
A method of administering insulin to a patient to achieve and maintain euglycemia is disclosed. The method includes administering insulin to the patient at a drip rate that is based on a current blood glucose level of the patient and a weight of the patient. Insulin is administered during an initial phase, a transition phase (during which blood glucose level decreases slower than during the initial phase), and a maintenance phase. During the maintenance phase, the method includes adjusting the drip rate periodically based on a current drip rate and a percentage change in blood glucose level during a period of time. In addition, the maintenance phase considers a lookback period in which the drip rate is adjusted based on trends during the lookback period.
Nº publicación: EP4724120A1 15/04/2026
Solicitante:
TANDEM DIABETES CARE INC [US]
Resumen de: US2024408303A1
0000 Disclosed herein are systems and methods for providing an alert to a user when preservative values in insulin formulations are expected to be low. Variables that affect preservative loss in insulin can be tracked by an insulin pump while insulin is being delivered by the pump. If the variables indicate that preservative values are below a threshold, an alert can be provided on the pump instructing the user to replace the insulin and/or implement another corrective action.
BOPI
Sede Electrónica
